Washington, D.C. 20002, or call (202) 512–7350.

Authority: Federal Advisory Committee Act. Pub. L. No. 92–463, Section 10(a)(2), 86 Stat. 770, 774 (1972) (current version at 5 U.S.C. app. section 10(a)(2) (1988); 41 CFR 101–6.1015 (1990).

Dated: September 10, 1996.

Ronald S. Young,

Executive Director.

[FR Doc. 96–24070 Filed 9–18–96; 8:45 am]

BILLING CODE 1610–01–M

GENERAL SERVICES ADMINISTRATION

Public Buildings Service; Notice of Availability of Final Supplemental Environmental Impact Statement; Proposed Pacific Highway Port of Entry Expansion, Blaine, Whatcom County, WA

Pursuant to section 102(2)(C) of the National Environmental Policy Act (NEPA) of 1969, as amended, as implemented by the Council on Environmental Quality (40 CFR Parts 1500–1508), the General Services Administration (GSA) has filed with the Environmental Protection Agency, and made available to other government and interested private parties, the Final Supplemental Environmental Impact Statement (FSEIS) for the proposed expansion at the Pacific Highway Port of Entry in Blaine, Washington.

The FSEIS is on file and a copy may be obtained from U.S. General Services Administration, Region 10, Attention: Donna M. Meyer, 400 15th Street, SW., Auburn, Washington 98001, (206) 931–7675. A limited number of copies of the FSEIS are available to fill single copy requests. Loan copies are available for public review at the Blaine City Library, 610 Third Street, Blaine, Washington.

Written commends regarding the Final Supplemental Environmental Impacted Statement may be submitted until October 14, 1996 and should be addressed to General Services Administration in care of GSA's EIS subconsultant, Berger/ABAM Engineers, Inc., 33301 Ninth Avenue South, Federal Way, Washington, 98003–6395.

Dated: September 6, 1996.

L. Jay Pearson,

Regional Administrator (10A).

[FR Doc. 96–24020 Filed 9–18–96; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Ceftiofur Sodium for Sheep; Availability of Data

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of target animal safety and effectiveness, and human food safety data to be used in support of a new animal drug application (NADA) or supplemental NADA for the use of ceftiofur sodium sterile powder, reconstituted with sterile water, as an injectable for treating certain respiratory diseases of sheep. The data, contained in Public Master File (PMF) 5544, were compiled under National Research Support Project-7 (NRSP–7), a national agricultural research program for obtaining clearances for use of new drugs in minor animal species and for special uses.

ADDRESSES: Submit NADA's or supplemental NADA's to the Document Control Section (HFV–199), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

FOR FURTHER INFORMATION CONTACT: Naba K. Das, Center for Veterinary Medicine (HFV–133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1659.

SUPPLEMENTARY INFORMATION: The use of ceftiofur sodium sterile powder, reconstituted as a sterile aqueous injection, to treat sheep for respiratory disease is a new animal drug use under section 201(v) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321(v)). As a new animal drug, ceftiofur is subject to section 512 of the act (21 U.S.C. 360b), which requires that its uses in sheep be the subject of an approved NADA or supplemental NADA. Sheep are a minor species under § 514.1(d)(1)(ii) (21 CFR 514.1(d)(1)(ii)).

The NRSP–7 Project, Western Region, University of California, Davis, CA 95616, has provided data and information that demonstrate safety and effectiveness to the target animal and human food safety for ceftiofur sterile powder, reconstituted as a sterile aqueous injectable solution for intramuscular use in sheep, to treat sheep respiratory disease (pneumonia) associated with *Pasteurella haemolytica* and/or *P. multocida*. NRSP–7 did not provide information concerning potential environmental impacts of the manufacturing process. Such information is required upon submission of an application relying on this file to support approval.

The data and information on safety and effectiveness are contained in PMF 5544. Sponsors of NADA's or supplemental NADA's may, without further authorization, reference the PMF to support approval of an application filed under § 514.1(d). An NADA or supplemental NADA must include, in addition to a reference to the PMF, animal drug labeling and other information needed for approval, such as data supporting extrapolation from a major species in which the drug is currently approved, or authorized reference to such data, and data concerning manufacturing methods, facilities and controls, and information addressing potential environmental impacts of the manufacturing process.

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information in this PMF submitted to support approval of an application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Dated: September 4, 1996.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 96–24074 Filed 9–18–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0074]

Sperti Drug Products, Inc., et al.; Withdrawal of Approval of 40 New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing 40 new drug applications (NDA's). The basis for the withdrawals is that the holders of the applications have repeatedly failed to file required annual reports on these NDA's.

EFFECTIVE DATE: September 19, 1996.

FOR FURTHER INFORMATION CONTACT: Olivia A. Vieira, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1046.

SUPPLEMENTARY INFORMATION: The holders of approved applications to

market new drugs or antibiotics for human use are required to submit annual reports to FDA concerning each of their approved applications in accordance with § 314.81 (21 CFR 314.81).

In the Federal Register of March 12, 1996 (61 FR 9999), FDA offered an opportunity for a hearing on a proposal to withdraw approval of 41 NDA's because the firms had failed to submit the required annual reports for these NDA's.

The agency received one request for a hearing from ConvaTec, P.O. Box 147, St. Louis, MO 63166–0147, the firm that bought Calgon Vestal Laboratories. ConvaTec has filed an annual report for 17–424, Septisol Foam. Therefore, approval of this NDA is not being withdrawn.

The holders of the other 40 applications did not respond to the notice of opportunity for hearing. Failure to file a written notice of participation and request for a hearing as required by 21 CFR 314.200 constitutes an election by the applicant not to make use of the opportunity for a hearing concerning the proposal to withdraw approval of the applications and a waiver of any contentions concerning the legal status of the drug products. Therefore, the Director, Center for Drug Evaluation and Research, is withdrawing approval of the NDA's listed in the table in this document.

NDA no.	Drug	Applicant
NDA 4–749	Bio-Dyne Ointment	Sperti Drug Products, Inc.
NDA 8–532	Nicodrin Tablets	Gold Leaf Division, Ormont Drug and Chemical Co., Inc.
NDA 8–685	Puran Tablets	Pure Laboratories, Inc.
NDA 8–891	Buffered Parasal-INH and INH 20 Tablets	Panray Division, Ormont Drug and Chemical Co., Inc.
NDA 10–353	Parasal-Potassium Tablets	Do.
NDA 11–902	Hematainer	Courtland Laboratories.
NDA 12–432	Meprobamate Tablets	Gyma Labs.
NDA 12–435	Nitrofurantoin Tablets	Do.
NDA 12–513	Petranquil (Meprobamate) Tablets	Pharmaceutical Philadelphia and Cosmetic Co.
NDA 12–866	Meprobamate Tablets	Riverton Laboratories.
NDA 12–984	Secret Cream Deodorant	The Procter and Gamble Co.
NDA 14–344	Meprobamate Tablets	Bryant Pharmaceutical, Corp.
NDA 14–364	Meprobamate Tablets	Bates Laboratories, Inc.
NDA 14–365	Meprobamate Tablets	Philadelphia Laboratories, Inc.
NDA 14–367	Meprobamate Tablets	American Pharmaceutical Co., Inc.
NDA 14–368	Meprobamate Tablets	MK Laboratories, Inc.
NDA 14–509	Meprobamate Tablets	Chase Chemical Co.
NDA 14–511	Meprobamate Tablets	Davis-Edwards Pharmacal Corp.
NDA 14–600	Meprobamate Tablets	Vitamix Pharmaceuticals, Division of Philadelphia Pharmaceutical and Cosmetic Co.
NDA 14–769	Meprobamate Tablets	USV Pharmaceuticals.
NDA 14–862	Meprobamate Tablets	Gold Leaf Pharmacal Co., Inc.
NDA 15–081	Meprobamate Tablets	Kirkman Laboratories, Inc.
NDA 15–170	Meprobamate Tablets	Schlicksup Drug (FAS–CILE 400 and FAC–CILE 200) Co., Inc.
NDA 15–437	Meprobamate Tablets	Phoenix Laboratories, Inc.
NDA 16–051	Meprobamate Tablets	Lit Drug Co.
NDA 16–068	Meprobamate Tablets	Leeds-Dixon Laboratories, Inc.
NDA 16–107	Protran *COM001*(Meprobamate)Tablets	Rand Laboratories, Inc.
NDA 16–254	Meprobamate Tablets	Modern Drugs, Inc.
NDA 16–731	Cuticura Medicated Soap	Purex.
NDA 17–240	Bio/Dopa (Levodopa) Capsules	Steri-Med.
NDA 17–343	Actin-N NitrofurazoneTopical Dressing	Sherwood Medical Co.
NDA 17–417	Westasept Topical Solution	West Chemical Products, Inc.
NDA 17–418	Wescohex Emulsion	Do.
NDA 17–419	Wescohex Topical Emulsion	The Vitarine Co., Inc.
NDA 17–423	Septisol Solution	Calgon Vestal Laboratories.
NDA 17–460	Septi-Soft Solution	Do.
NDA 17–540	Heparin Sodium Injection	Dell Laboratories.
NDA 17–544	Dancon Antidandruff Shampoo	The Wella Corp.
NDA 17–580	Dancon Antidandruff Shampoo	Do.
NDA 18–363	Hexascrub Sponge	Professional Disposables, Inc., Division of Nice-Pak Products, Inc.

The Director, Center for Drug Evaluation and Research, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), and under authority of 21 CFR 5.82, finds that the holders of the applications listed above have repeatedly failed to submit reports required by § 314.81. Therefore, under this finding, approval of the NDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 19, 1996.

Dated: August 28, 1996.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 96–24075 Filed 9–18–96; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4086–N–39]

Office of the Assistant Secretary for Housing-Federal Housing Commissioner; Notice of Proposed Information Collection for Public Comment

AGENCY: Office of the Assistant Secretary for Housing-Federal Housing Commissioner, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: Comments due: November 18, 1996.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Oliver Walker, Housing, Department of Housing and Urban Development, 451–7th Street SW., Room 9116, Washington, DC 20410.

FOR FURTHER INFORMATION CONTACT: Natalie Yee, Single Family Insurance Operations Division (SFIOD), Telephone number (202) 708–0614 ext. 3500 for information on the Single Family Premium Collection Subsystem Upfront (formerly form HUD–27001, Transmittal of Upfront Mortgage Insurance Premium) (this is not a toll-free number).

SUPPLEMENTARY INFORMATION: The Department will submit the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).

The Notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

This Notice also lists the following information:

Title of Proposal: Single Family Premium Collection Subsystem Upfront.

OMB Control Number: 2502–0423.

Description of the need for the information and the proposed use: The new Single Family Premium Collection Subsystem (SFPCS) replaces the A83 One-Time Mortgage Insurance Premium System. The form HUD–27001, Transmittal of Upfront Mortgage Insurance Premium is now obsolete. However, the information collection is still in effect. SFPCS will strengthen HUD's ability to manage and process single family mortgage insurance premium collections and corrections for the majority of insured single family mortgages. It also will improve data integrity for the Single Family Insurance Program. FHA approved lenders will use the new versions of Melon's Telecash and HUD Mortgage Premium Connection (HUD–MPC) software for all transmissions with SFPCS. SFPCS replaces the old A83 system and the form HUD–27001 which lenders used to remit Upfront Mortgage Insurance Premiums using funds obtained from the mortgagor during the closing of the mortgage transaction at settlement. The authority for this collection of information is specified in 24 CFR 203.284. The collection of information is used to update HUD's Single Family Insurance System. Without this information the premium collection/monitoring process would be severely impeded and program data would be unreliable. In general lenders use the new software remit the upfront premium through SFPCS to obtain mortgage insurance for the homeowner.

Agency form numbers: Not applicable.

Members of affected public: Business or other for-profit.

Public reporting burden for this collection of information is estimated to average 0.5 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. The burden of completing the form will be eliminated. Lenders will be able to key the information online or have their computer transmit the information. The number of respondents is 3,378 and the frequency of response is on occasion, that is a specific event, a mortgage closing. Since remittance is made through the Automatic Clearinghouse, the upfront remittance is submitted electronically and there is no paperwork to complete and mail in. Status of the proposed information collection: Extension of a currently approved collection.

Authority: Section 3506 of the Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended.

Dated: September 12, 1996.

Nicolas P. Retsinas,

Assistant Secretary for Housing-Federal Housing Commissioner.

[FR Doc. 96–23961 Filed 9–18–96; 8:45 am]

BILLING CODE 4210–27–M

[Docket No. FR–4086–N–47]

Office of the Assistant Secretary for Housing; Notice of Proposed Information Collection for Public Comment

AGENCY: Office of the Assistant Secretary for Housing, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: November 18, 1996.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Oliver Walker, Housing, Department of Housing & Urban Development, 451–7th Street, SW., Room 9116, Washington, DC 20410.

FOR FURTHER INFORMATION CONTACT: Barbara D. Hunter, Telephone number (202) 708–3944 (this is not a toll-free number) for copies of the proposed forms and other available documents.

SUPPLEMENTARY INFORMATION: The Department will submit the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).

The Notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to: